Multiple Myeloma Treatments

Treatments in Development

The following is a list of treatments in development for multiple myeloma that are currently recruiting myeloma patients in the United States. You can use the buttons below to filter by diagnosis and sort the listings by name, distance as well as active number of trials.


Other ways to search
Find a trial that's right for you by personalizing your search.
Browse our myeloma treatment center directory to find a myeloma specialist near you.

Sort By Distance

Need Help?

Call SparkCures and one of our clinical trial specialists will help answer your questions.

(888) 828-2206

ACP-196
ACP 196 is a new drug being investigated as a treatment for myeloma that belongs to a class of drugs known as bruton tyrosine kinase inhibitors.
Allogeneic Transplant
Allogeneic Transplant is a type of stem cell transplant that utilizes a donor (not from own) pre-collected stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.
AMG 176
AMG 176 is an MCL-1 inhibitor (myeloid cell leukemia-1) that can prevent cancer cells from creating proteins to protect itself, and can cause cell death.
AMG 224
AMG-224 is a new drug being tested in myeloma called an antibody-drug conjugate. It consists of a chemotherapy drug combined with a monoclonal antibody which helps to deliver the drug to myeloma cells.
Atezolizumab
Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.
Autologous Transplant
Autologous Transplant is a type of stem cell transplant that utilizes the patient's pre-collected own stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.
Axitinib (Inlyta)
Axitinib is a small cell tyrosine kinase inhibitor targets that blocks cancer cells from creating new blood vessels. It’s currently FDA approved for use in Renal Cell Carcinoma, and undergoing trials for use in other cancers, including multiple myeloma.
Azacitidine (Vidaza)
Azacitidine is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat myelodysplastic syndromes (MDS). It is also being studied in the treatment of other types of cancers, including multiple myeloma.
bb2121
bb2121 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily. When it finds myeloma cells, bb2121 removes and destroys them.
bb21217
bb21217 is a new treatment being investigated in myeloma that belongs to a type of immunotherapy known as chimeric antigen receptor T-cell (CAR-T) therapy. This involves T-cells being taken from the patient and being changed to find myeloma cells more easily. When it finds myeloma cells, bb21217 removes and destroys them.
Bendamustine (Treanda)
Bendamustine is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). It is also being studied in the treatment of other types of cancers, including multiple myeloma.
BL-8040
BL-8040 is a novel CXC4 antagonist that blocks chemicals in the cancer cell responsible for growth and division and blood vessel development.
Bortezomib (Velcade)
Bortezomib is used to treat multiple myeloma and mantle cell lymphoma. It is a cancer medicine that interferes with the growth and spread of cancer cells in the body. Bortezomib is given as an injection under the skin (subcutaneously) or injected into a vein through an IV.
Bosutinib (Bosulif)
Bosutinib is a Tyrosine Kinase Inhibitor that blocks receptors in the cancer cell that promote cell division.
Busulfan (Myleran, Busulfex)
Busulfan is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat chronic myelogenous leukemia (CML). It is also being studied in the treatment of other types of cancers, including multiple myeloma.
Carfilzomib (Kyprolis)
Carfilzomib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is approved for use with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma in patients who have received one to three prior lines of therapy.
CC-122
CC-122 is a first in class pleiotropic pathway modulator that binds the special protein complexes in the cell, leading to anti-proliferation of cancer cells and improved immune system functions against cancer cell growth.
CC-486
CC-486 is an oral azacitidine that is metabolized to 5-azadeoxycitidine triphosphate and reversibly inhibits DNA methyltransferase and blocks DNA methylation leading to cancer cell death.
Cetuximab (Erbitux)
Cetuximab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat colorectal cancer and squamous cell carcinoma of the head and neck. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
CLR 131
CLR 131 is an investigational compound under development for a range of hematologic malignancies. It is currently being evaluated in a Phase I clinical trial in patients with relapsed or refractory multiple myeloma.
Cobimetinib (Cotellic)
Cobimetinib is a mitogen-activated protein kinase inhibitor that blocks chemicals in the cancer cell responsible for growth and division.
CPI-0610
CPI-0610 inhibits Bromodomain and Extra-Terminal (BET) family of proteins, disrupting chromatin remodeling and gene expression that eventually lead to inhibition of cancer cell growth.
Crizotinib (Xalkori)
Crizotinib is a CLK and ROS1 Inhibitor that blocks chemicals in the cell responsible for cell growth, division and in some cases, blood vessel growth.
Dabrafenib (Tafinlar)
Dabrafenib is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat melanoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
Daratumumab (Darzalex)
Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.
Dendritic Cell Fusion Vaccine
Dendritic Cell Fusion Vaccines are a type of immunotherapy where our own cells, in this case, dendritic cells, are loaded with tumor antigens to help the immune system recognize and mount a response to those cancer cells present in the body.
Denosumab (Xgeva)
Denosumab is a humanized monoclonal antibody that binds to RANKL and blocks the interaction of RANKL with RANK, resulting in inhibition of bone destroying cells and a decrease in bone breakdown.
EDO-S101
EDO-S101 is a first in class fusion drug that combines an HDAC inhibitor with bendamustine and vorinostat. EDO-S101 can work both by damaging the cancer cells DNA and preventing it from repairing itself.
Elotuzumab (Empliciti)
Elotuzumab is a drug used for the treatment of multiple myeloma. It is for use in patients who have received one to three prior medications and is intended to be used in combination with lenalidomide and dexamethasone. It is given as an injection into a vein through an IV.
Erlotinib (Tarceva)
Erlotinib is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat non-small cell lung cancer and pancreatic cancer. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
Everolimus (Afinitor)
Everolimus is approved to treat breast cancer, pancreatic cancer, and renal cell carcinoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
GBR 1342
GBR 1342 is a humanized, bispecific monoclonal antibody (bsAb) that is designed to activate the patient's immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors.
GSK525762
GSK525762 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as BET Inhibitors.
Ibrutinib (Imbruvica)
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling, which may result to decreased growth of cancer cells.
INCB050465
INCB050465 is a PI3K-delta inhibitor that can work by blocking chemicals in the cancer cell that are responsible for growth and division, and by sometimes inducing cell death.
INCB052793
INCB052793 is a JAK1 inhibitor that can work by blocking chemicals in the cancer cell that are responsible for rapid cell growth and division.
INCB053914
INCB053914 is a pan-PIM inhibitor that can work by blocking specific chemicals in the cancer cell that block some cells from dividing and growing.
INCB054828
INCB054828 is an FGFR inhibitor that can work by blocking specific chemicals in the cancer cell that tell cancer cells to grow and divide rapidly.
INCB057643
INCB057643 is a BET inhibitor that can work by stopping chemicals in the cancer cell that tell it to grow and divide.
Ipilimumab (Yervoy)
Ipilimumab is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat melanoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
Isatuximab
SAR650984 is a humanized IgG1 monoclonal antibody that binds to CD38+ cells, triggerring antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and tumor programmed cell death.
Ixazomib (Ninlaro)
Ixazomib is an oral proteasome inhibitor that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
KITE-585
KITE-585 is a chimeric antigen receptor T-cell therapy. It targets a protein called B-cell maturation antigen, or BCMA, that is found on the surface of most multiple myeloma tumors.
Lenalidomide (Revlimid)
Lenalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is given as an oral medication.
Measles Virus
Cancer treatment with the Measles Virus can work by modifying the virus to only infect cancer cells. Once injected into the body, the virus then can seek out and kill the cancer cells.
Melflufen
Melflufen is a modified version of the chemotherapy drug melphalan that is being investigated as a treatment for myeloma.
Methotrexate (Folex, Mexate, MTX, Methotrex)
Natural Killer (NK) Cells
Natural Killer Cells can work in cancer treatment by being modified to recognize and attack tumor cells in the body. Natural Killer Cells are already found in the body, and are unique because they are able to recognize and attack cells without being acted upon by an antigen (immunization).
Nivolumab
Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
ONC201
ONC201 is a first in class anti tumor drug that can work by producing stress chemicals in the cancer cell and blocking it from growing and dividing.
P-BCMA-101
P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a "safety switch" gene to allow the cells to be eliminated if desired.
Palbociclib
Palbociclib is an oral drug that inhibits cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), blocking retinoblastoma (Rb) protein phosphorylation that leads to cell cycle arrest and cancer cell death.
Panobinostat (Farydak)
Panobinostat is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It has been approved to be used in combination with bortezomib and dexamethasone to treat people with multiple myeloma who have received at least two other standard treatments (including bortezomib and an immunomodulating agent).
Pembrolizumab (Keytruda)
One way your immune system controls the activity of T cells is through the PD-1 pathway. Some cancer cells can hide from the T cells attack by taking control of the PD-1 pathway. This stops T cells from attacking cancer cells. Pembrolizumab works by blocking the PD-1 pathway. The Keynote Clinical Trials are studying whether pembrolizumab can help treat patients with various types of cancer.
Pertuzumab (Perjeta)
Pertuzumab is a monoclonal antibody that is modified to try and trigger the immune system to attack specific cancer cells.
Pneumococcal 13-Valent Conjugate Vaccine (Prevnar 13)
Prevnar 13 is a vaccine containing 13 different strains of the bacterium Streptococcus pneumoniae for the prevention of pneumococcal disease in immunocompromised patients with cancer.
Pomalidomide (Pomalyst)
Pomalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is used in combination with dexamethasone to treat people with relapsed/refractory multiple myeloma who have received at least two prior medicines to treat their myeloma (including a type of medicine known as a proteasome inhibitor and lenalidomide).
PVX-410
PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.
Reolysin
Reolysin is a serotype 3 Dearing strain (T3D) of reovirus that replicates and induces programmed tumor cell death in RAS-activated tumor cells.
RO6870810
RO6870810 is a new drug being investigated as a treatment for myeloma and other cancers. It belongs to a class of drugs called Bromodomain and Extra-Terminal Protein (BET) Inhibitors.
Selinexor
Selinexor is the first in a new class of drugs being investigated as a treatment for myeloma. It belongs to a class of drug called selective inhibitor of nuclear export (SINE) and works by disrupting survival mechanisms in myeloma cells.
SGN-CD352A
SGN-CD352A is an antibody drug conjugate that can work by targeting specific areas of the cancer cell, attacking it, and inducing rapid cell death.
Sotatercept
Sotatercept binds to activin, inhibiting its binding to ActRIIA and ActRIIA signaling, resulting in the stimulation of bone building activity and the inhibition of bone destroying activity, resulting in bone formation and increased bone mineral density and strength.
SurVaxM
SurVaxM is a first-of-its-kind, patented peptide mimic immunotherapeutic vaccine (immunotherapy) that targets survivin, a cell-survival protein present in 95 percent of glioblastomas and many other cancers. It is engineered to recognize survivin-expressing cancer cells as foreign and stimulate patients’ own immune response to control tumor growth and recurrence.
Survivin Vaccine
Survivin Vaccine can work by stimulating the immune system to create T-Cells that recognize and attack Survivin, a tumor antigen.
T Cells
A T cell or T lymphocyte is a type of lymphocyte (a subtype of white blood cell) that plays a central role in cell-mediated immunity.
TAS4464
TAS4464 is an investigational NEDD8 activating enzyme (NAE) inhibitor, a compound which may affect cancer cell growth and survival.
Temsirolimus (Torisel)
Temsirolimus is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat renal cell carcinoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
Trametinib (Mekinist)
Trametinib is a cancer medication that interferes with the growth and spread of cancer cells in the body. It is approved to treat melanoma. It is also being studied in the treatment of other types of cancers, including multiple myeloma.
Trastuzumab (Herclon, Herceptin)
Trastuzumab is a monoclonal antibody that can work by targeting HER2 receptors in some cancer cells that are responsible for telling the cancer cells to grow and divide rapidly.
Trivalent Influenza Vaccine
Trivalent Influenza Vaccine is an annually formulated vaccine that contains the three strains of influenza projected to be prevalent in the coming season.
Venetoclax
ABT-199 is an anti-apoptotic protein Bcl-2 inhibitor that mimics BH3-only proteins, the native ligands of Bcl-2 and programmed cell death activators, repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.
Yeliva
Yeliva (ABC294640) is a new drug being investigated as a treatment for myeloma. It is administered orally and has anti-cancer and anti-inflammatory activities.